Stock RGBPP REGEN BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Regen BioPharma, Inc. Share Price OTC Markets

Equities

RGBPP

US75886M4096

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 10:58:14 17/06/2024 pm IST 		5-day change 1st Jan Change
1.5 USD +48.51% Intraday chart for Regen BioPharma, Inc. 0.00% -36.40%
24/04 Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
09/02 Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells CI

Financials

Sales 2022 236K 19.66M Sales 2023 237K 19.75M Capitalization 6.33M 528M
Net income 2022 2M 167M Net income 2023 1M 83.48M EV / Sales 2022 144 x
Net Debt 2022 1.22M 102M Net Debt 2023 635K 53.02M EV / Sales 2023 29.4 x
P/E ratio 2022
13.7 x
P/E ratio 2023
6.24 x
Employees 1
Yield 2022 *
-
Yield 2023
-
Free-Float 99.99%
More Fundamentals * Assessed data

Chart Regen BioPharma, Inc.

Dynamic Chart

Latest news about Regen BioPharma, Inc.

Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells CI
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program CI
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program CI
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly CI
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies CI
Regen BioPharma, Inc. announced that it has received $0.14875 million in funding CI
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
Regen BioPharma, Inc. Announces Board Appointments CI
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Regen BioPharma, Inc. Auditor Raises 'Going Concern' Doubt CI
More news

Press releases Regen BioPharma, Inc.

Regen BioPharma : Material Event - Form 8-K PU
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024 PR
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer AQ
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023 PR
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K) AQ
More press releases

Quotes and Performance

1 day+48.51%
Current month-11.11%
1 month+47.06%
3 months-25.74%
6 months-36.40%
Current year-36.40%
More quotes

Highs and lows

1 month
1.01
Extreme 1.01
1.76
Current year
1.01
Extreme 1.01
3.52
1 year
1.01
Extreme 1.01
5.75
3 years
1.01
Extreme 1.01
582.57
5 years
1.01
Extreme 1.01
582.57
10 years
1.01
Extreme 1.01
899.96
More quotes

Managers and Directors - Regen BioPharma, Inc.

Managers TitleAgeSince
David Koos CEO
 Chief Executive Officer 64 24/12/24
Members of the board TitleAgeSince
David Koos CEO
 Chief Executive Officer 64 24/12/24
More insiders

Quotes

Date Price Change Volume

Delayed Quote OTC Markets, June 17, 2024 at 10:58 pm IST

More quotes

Company Profile

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients. tCellVax is a cell-based immunotherapy that stimulates the patient’s immune system through gene silencing of NR2F6.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.49% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.73% 115B
ARGENX SE Stock argenx SE
+22.50% 26.64B
BIONTECH SE Stock BioNTech SE
-21.81% 19.91B
GENMAB A/S Stock Genmab A/S
-16.89% 16.32B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.81% 15.49B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.74% 15.52B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+62.72% 14.83B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.09% 13.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RGBP Stock
  4. RGBPP Stock